Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicOTCMKTS:AVXL
Date2/2007
Raised
Post IPO Valuation

General Information

Offices

New York, USA
51 West 52nd Street
7th floor
New York, NY 10019, USA

People

Chief Executive Officer (CEO)
Director
Scientific Advisory Board
Scientific Advisory Board
Scientific Advisory Board
Scientific Advisory Board
Scientific Advisory Board
Scientific Advisory Board

Funding

TOTAL $2.6M
FUNDING TOTAL $2.6M
Private Equity, 7/2013
$2.6M
DEBT TOTAL $10M
Post IPO Debt, 3/2014
$10M

Tags

Anavex

Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term.

Recent Milestones

Videos

Screenshots

Stock Price

Sources

  1. Anavex raises $2.6-million in private placement and conversion of liabilities, enters into $10-million financing commitment and appoints CEO (firstwordpharma.com) [edit]
  2. Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial (biospace.com) [edit]
Edit This Page
Last Edited 3/19/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy